CPT 88344Laboratory

Imhchem/imcytchm ea mlt antb

CPT 88344 covers the laboratory work of applying each additional antibody stain to tissue or cell samples under a microscope to identify specific proteins, helping doctors diagnose cancer and other diseases. This is an add-on code used after the first antibody stain is performed.

Showing rates for

National Average

Base Medicare rate

$167.23

This calculator gives a typical-case estimate using standard Medicare modifier rules. Actual payment depends on payer policies, documentation, code-specific CMS status indicators, and locality. Verify before billing.

RVU breakdown

Work RVU

0.77

PE RVU (NF)

4.38

MP RVU

0.02

Total RVU

5.17

Conversion factor: 32.3465 · Source: CMS MPFS RVU25A · Confidence: High

NCCI bundling edits

Loading bundling edits…

Billing tips

Bill each unique antibody clone separately with 88344 - for a 5-antibody IHC panel, report 88342 x1 plus 88344 x4 units to capture all four additional antibodies
Impact: Proper unit reporting captures $668.92 for four additional antibodies versus undercoding at one unit losing $501.69 in legitimate revenue
Document the specific antibody clone and manufacturer for each 88344 unit in the pathology report to support medical necessity and withstand audits
Impact: Detailed antibody documentation reduces denial rates by 40-60% and provides defensible audit trail; generic descriptions like 'additional stains' trigger payer scrutiny
Verify LCD/LCA requirements for your MAC jurisdiction before ordering antibody panels - some Medicare contractors limit covered antibodies by diagnosis or restrict certain combinations
Impact: Proactive LCD compliance prevents denials; non-covered antibodies should be identified pre-service for ABN collection, protecting $167.23 per antibody from write-off
Never report 88344 alone - it must be paired with primary code 88342 (first antibody, manual method) or 88341 (first antibody, automated method) on the same claim
Impact: Standalone 88344 billing triggers automatic denial as an add-on code; proper sequencing with primary code ensures $167.23 payment per additional antibody
For reflex testing scenarios where additional antibodies are ordered after initial IHC results, ensure documentation explains medical necessity for the add-on antibodies to the original diagnostic question
Impact: Clear reflexive testing rationale reduces medical necessity denials by 35-50%; prevents downcoding of legitimate diagnostic workup worth $167.23 per antibody

Live Field Datano reports yet

Real billers contribute denial patterns and appeal strategies for this code. Once 5+ reports come in, you’ll see live aggregated data here — the only place this exists, free.

Working with CPT 88344?

Get the free Revenue Protection Toolkit — the denial triggers, modifier pitfalls, and bundling conflicts that quietly cost you reimbursement. Instant download.

Help build the field knowledge

MedPayIQ gets smarter as billers contribute. If you've had this code denied, share what happened so others learn from it. Anonymous, no patient info.

Related actions

Frequently asked questions

What is the Medicare reimbursement rate for CPT code 88344 in 2025?

The 2025 Medicare national average reimbursement rate for CPT 88344 is $167.23 for both facility and non-facility settings. This rate is based on 5.17 total RVUs multiplied by the 2025 conversion factor of 32.3465. Actual payment may vary by geographic locality based on GPCI adjustments.

How many times can you bill CPT 88344 on the same date of service?

You can bill 88344 multiple times (multiple units) on the same date of service, with each unit representing one additional unique antibody stain beyond the first. There is no absolute Medicare limit, but medical necessity must support each antibody. Panels exceeding 6-8 antibodies often trigger payer review, requiring documentation justifying the comprehensive workup for the specific diagnostic scenario.

What is the difference between CPT 88342 and 88344?

CPT 88342 is the primary code for the first antibody stain using manual methodology in immunohistochemistry or immunocytochemistry, while 88344 is an add-on code for each additional antibody beyond the first. You must always bill 88342 (or 88341 for automated methods) first, then add 88344 for each subsequent antibody in the panel. For example, a 4-antibody panel would be coded as 88342 x1 plus 88344 x3.

Does CPT 88344 include professional interpretation?

No, CPT 88344 is a technical component code representing the laboratory work of performing the additional antibody stain. The professional interpretation is included in the primary IHC codes (88342 or 88341). Pathologist interpretation services for the entire IHC panel, including all additional antibodies, are bundled into the primary code professional component. Modifier 26 should never be appended to 88344.

What documentation is required to bill CPT 88344?

Each unit of 88344 requires documentation of the specific antibody clone name, manufacturer, individual stain result interpretation, and how it contributed to the diagnosis. The pathology report must list each antibody separately with corresponding findings. Control results (positive and negative) should be documented. Medical necessity for each antibody in the panel must be evident from the clinical scenario, and the diagnostic question requiring IHC workup should be clearly stated.

Can CPT 88344 be billed for flow cytometry antibodies?

No, CPT 88344 is specifically for immunohistochemistry (tissue sections) and immunocytochemistry (cell preparations) techniques, not flow cytometry. Flow cytometry uses different CPT codes in the 88184-88189 series. Billing 88344 for flow cytometry antibodies will result in denial and potential audit findings. The code descriptor specifically refers to IHC/ICC methodologies applied to slides for microscopic visualization.

What are common reasons for CPT 88344 claim denials?

The most common denials include: billing 88344 without the required primary code (88342 or 88341), medical necessity challenges for large antibody panels, lack of specific antibody documentation in the pathology report, duplicate service edits when multiple units are billed, LCD non-coverage for specific antibody-diagnosis combinations, and insufficient documentation of how each additional antibody contributed to diagnosis. Proper documentation and understanding of local coverage determinations prevent most denials.